VivoSeq
Dermatology

Keloid

39

Pipeline Programs↗

13

Active Trials↗

18

Companies Involved↗

Keloid is a moderately active landscape with 39 programs across 18 companies. The most active players are AiViva BioPharma, Inc., Capstone Therapeutics, GSK. 11 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

22/100

Mech. Concentration

31/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

AiViva BioPharma, Inc.

1 program

Phase 1C

Capstone Therapeutics

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2M

miRagen Therapeutics, Inc.

1 program

Phase 2O

Ong Kim Yao

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical9

68ga-RGD

Peking Union Medical College Hospital

Methylprednisolone Acetate

Montefiore Medical Center

Triamcinolone Hexacetonide

Ethypharm

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Intralesional Triamcinolone Acetonide

Johns Hopkins University

Phase 12

Calcium Chloride

Pfizer

AIV001

AiViva BioPharma, Inc.

Phase 213

Bevacizumab

Bio-Thera Solutions

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Sorafenib

Bayer

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Ritlecitinib

Pfizer

Phase 34

Pirfenidone

Legacy Health System

Intralesional Triamcinolone

Centro Dermatológico Dr. Ladislao de la Pascua

Bryhali

Icahn School of Medicine at Mount Sinai

Duobrii

Icahn School of Medicine at Mount Sinai

Approved11

Dexamethasone

Aspen Global Incorporated

Triamcinolone

Bassett Healthcare

Imiquimod

Bausch Health Americas, Inc.

Sirolimus

Prism Pharmaceuticals

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Analysis

Modality Breakdown

84%

Small molecule

51 of 61 classified programs — the dominant modality here.

16%ALL OTHERSCell therapy58%Monoclonal antibody23%Protein / enzyme12%RNA therapy12%Radiopharmaceutical12%

Small molecule leads; the ring shows all 61 classified programs, each share of the total. Modality classified for 98% of 64 pipeline programs.

Analysis

Trial Status

63

clinical trials

Completed34 · 54%
Unknown status8 · 13%
Terminated7 · 11%
Recruiting5 · 8%
Not yet recruiting5 · 8%
Active, not recruiting3 · 5%
Other1 · 2%

Clinical Trials

Trial Activity

63 trials

Topical Cryotherapy and Keloid/Hypertrophic Scars
Recruiting·—·Phase 3·NCT07336368·30 enrolled
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT06373458·30 enrolled
Intralesional Treatment of Keloids
Recruiting·SSohag University·Phase 3·NCT06729840·45 enrolled
Mechanisms Of Keloid Fibroblast Activation And Potential Therapeutic Targets: A Tissue-Based Translational Study
Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·N/A·NCT07682636·20 enrolled
Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT
Recruiting·PPeking Union Medical College Hospital·Preclinical·NCT07660406·30 enrolled
The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment
Active, not recruiting·UUniversitas Padjadjaran·Phase 2·NCT06814288·20 enrolled
Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
Active, not recruiting·KKasr El Aini Hospital·Phase 4·NCT07014280·28 enrolled
Comparison of Recurrence Rate of Keloid After Excision Between Intra-operative Steroid Injection and Steroid With Platelet-rich Plasma Injection Combination Therapy
Active, not recruiting·RRamathibodi Hospital·Phase 2·NCT06965088·212 enrolled
Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment
Not yet recruiting·NNishtar Medical University·Phase 4·NCT06897969·60 enrolled
The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.
Not yet recruiting·KKing Edward Medical University·N/A·NCT07201766·104 enrolled
Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.
Not yet recruiting·—·Phase 1/2·NCT06230146·45 enrolled
Small Interfering RNA (siRNA) Microneedle Patches on the Appearance of Ear Keloid Post-Surgical Scars: A Randomised Controlled Clinical Trial
Not yet recruiting·—·Phase 2·NCT07596628·158 enrolled
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids
Not yet recruiting·FFujian Medical University Union Hospital·Preclinical·NCT07679243·120 enrolled
Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars
Completed·RRenovo·Phase 1/2·NCT00469235·20 enrolled
A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars
Completed·CCapstone Therapeutics·Phase 2·NCT00825916·59 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)